This invention relates to the field of
biomedicine, specifically to a synergistic and targeted epigenetic pharmaceutical composition for the
treatment of lung cancer. In studies of
drug-resistant
lung cancer cells, it was found that overexpression of the NSUN7
gene in
drug-resistant
lung cancer cells can inhibit MZF1. L The expression of MZF1 also promotes S When the expression of NSUN7
gene was suppressed, no promotion of MZF1 was found. L The expression of MZF1 can be suppressed at the same time. S The expression of NSUN7
gene was inhibited, meaning no opposite result was obtained. However, when NSUN7
gene expression was inhibited and EGFR-TKI inhibitors were administered to
drug-resistant
lung cancer cells, MZF1 cells in drug-resistant
lung cancer cells showed a positive result. L Upregulation, MZF1 S Decreased expression of NSUN7 leads to the transformation of drug-resistant
lung cancer cells into drug-sensitive cells. Therefore, interfering with NSUN7 in combination with epigenetic drugs to regulate the
alternative splicing of
methylation-sensitive transcription factors can increase the specificity of regulatory targets and synergistically enhance the
in vitro and
in vivo antitumor effects.